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Structural Basis for Inhibition Promiscuity of Dual
Specific Thrombin and Factor Xa Blood
Coagulation Inhibitors
mogen factor X to its activated form, factor Xa. Com-
bined with factor Va and calcium ions on a phospholipid
membrane, factor Xa forms the prothrombinase com-
plex which converts prothrombin into thrombin. Throm-
bin very efficiently initiates fibrin formation, platelet ag-
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Thrombin and more recently, factor Xa have beenDiseases
Boehringer Ingelheim Pharma KG intensively investigated as targets for antithrombotic
therapy [2–7].88397 Biberach an der Riss
Germany Recent preclinical and clinical studies with protein-
aceous or small molecule agents have concentrated on
selective inhibition of either of the two proteinases [8,
9]. In contrast, anticoagulant strategies of haematopha-Summary
geous animals frequently involve multiple inhibition of
the blood coagulation cascade and platelet activationBackground: A major current focus of pharmaceutical
research is the development of selective inhibitors of [10–14]. For instance, the soft tick Ornithodorus mou-
bata prevents blood clotting through direct inhibitionthe blood coagulation enzymes thrombin or factor Xa
to be used as orally bioavailable anticoagulant drugs of thrombin by ornithodorin [15], of factor Xa by tick
anticoagulant peptide (TAP) [16–18] and inhibition ofin thromboembolic disorders and in the prevention of
venous and arterial thrombosis. Simultaneous direct in- platelet aggregation by moubatin [19, 20]. Other notori-
ous examples of blood sucking organisms with similarhibition of thrombin and factor Xa by synthetic protein-
ase inhibitors as a novel approach to antithrombotic strategies are the medicinal leech Hirudo medicinalis
[21] and the Mexican leech Haementeria officinalistherapy could result in potent anticoagulants with im-
proved pharmacological properties. [22, 23].
The targeting of several enzymes active within the
same physiological pathway therefore appears to be anResults: The binding mode of such dual specific inhibi-
tors of thrombin and factor Xa was determined for the evolutionarily favored strategy.
Moreover, heparin, a currently widely used anticoagu-first time by comparative crystallography using human
a-thrombin, human des-Gla (1–44) factor Xa and bovine lant, inhibits both thrombin and factor Xa indirectly via
complex formation with and modulation of the activitytrypsin as the ligand receptors. The benzamidine-based
inhibitors utilize two different conformations for the in- of the serine proteinase inhibitor (serpin) antithrombin
III (for review see [24]). This therapy suffers from a num-teraction with thrombin and factor Xa/trypsin, which are
evoked by the steric requirements of the topologically ber of weaknesses, e.g., lack of oral bioavailability, side
effects such as thrombocytopenia, and the necessity ofdifferent S2 subsites of the enzymes. Compared to the
unliganded forms of the proteinases, ligand binding in- intensive clinical monitoring, most of which are associ-
ated with the chemical nature of heparin itself.duces conformational adjustments of thrombin and fac-
tor Xa active site residues indicative of a pronounced A combination of thrombin and factor Xa inhibitory
activity in a single, synthetic, orally bioavailable, smallinduced fit mechanism.
molecular weight compound as a novel approach to
antithrombotic therapy should therefore result in potentConclusion: The structural data reveal the molecular
basis for a desired unselective inhibition of the two key anticoagulants with potentially superior features over
currently available therapies.components of the blood coagulation cascade. The 4-(1-
methyl-benzimidazole-2-yl)-methylamino-benzamidine Thrombin and factor Xa belong to the trypsin family
of serine proteinases. Structural data for thrombin [25,moieties of the inhibitors are able to fill both the small
solvent accessible as well as the larger hydrophobic S2 26], factor Xa [27], and trypsin [28] show strong similari-
ties of the S1 specificity pockets of the three enzymes.pockets of factor Xa and thrombin, respectively. Distal
fragments of the inhibitors are identified which fit into The S2 and S4 subsites show distinct topologies. While
S2 is covered by the 60 insertion loop (the sequenceboth the cation hole/aromatic box of factor Xa and the
hydrophobic aryl binding site of thrombin. Thus, binding nomenclature used is based on the topological equiva-
lences of the discussed enzymes with chymotrypsino-constants in the medium-to-low nanomolar range are
obtained against both enzymes. gen [29] and on the thrombin nomenclature suggested
by Bode et al. [30]) in thrombin and is hydrophobic in
nature, it is smaller and solvent accessible in factor XaIntroduction
and trypsin. The aryl binding site of thrombin above the
conserved residue Trp-215 is lined by residues Leu-99Activation of the extrinsic or intrinsic pathways of the
coagulation cascade leads to the conversion of the zy- and Ile-174. In factor Xa, this subsite is built by the
Key words: blood coagulation; factor Xa; thrombin; crystal struc-* To whom correspondence should be addressed (email: herbert.
nar@bc.boehringer-ingelheim.com). ture; inhibitor complexes
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crystal structures of active site inhibited factor Xa have
been solved and refined at low or medium resolution
and published [31, 34, 35].
We have determined crystal structures of two related
synthetic inhibitors, BIBT0871 and BIBR1109 (Figure 1), in
complex with their target proteinases, human a-thrombin
and human des-Gla (1–44) factor Xa, as well as their
complexes with bovine trypsin.
The crystal structure analyses were carried out at 1.9–
2.0 A˚ resolution (with the exception of the FXa-BIBR1109
complex at 3.0 A˚) resulting in high quality structures with
the expected low residual errors for atomic positionsFigure 1. Chemical Structures of the Dual Specific Blood Coagula-
tion Inhibitors Used in this Study (Table 1). The inhibitors are clearly defined in the experi-
mental electron densities in all cases (Figure 2). ForChemical topology of the 4-(1-methyl-benzimidazole-2-yl)-methyl-
amino-benzamidine scaffold (top) and the distal fragments (bottom) BIBT0871, the acetic ester substituent at the oximether
of BIBT0871, BIBR1109 and BIBM1015 (left to right) connected to is not in contact with the proteins and faces solvent
the scaffold at the position of the substituent R. channels in the crystals and is therefore disordered.
General Binding Mode of the Inhibitorscorresponding residues Tyr-99 and Phe-174, which to-
The inhibitors are benzamidine-based compounds thatgether with the indole ring system of Trp-215 form the
bind to the specificity pocket of all three enzymes in awalls of an aromatic box. In the back of this pocket,
similar way and form the expected twin-twin interactionamide carbonyl groups from the backbone around resi-
of their amidine moiety with the side chain of Asp-189due 99 form a distinct pattern of hydrogen bond ac-
at the bottom of the S1 subsite. The distal substituentsceptors in both enzymes with the thrombin 99-loop be-
of the inhibitors are aromatic ring systems that wereing one residue longer than in factor Xa. In the latter
designed to fit into the aryl binding sites of thrombinenzyme, the 99-loop carbonyls and the side chain of
and factor Xa. There is a N-methyl-benzimidazole scaf-E97 form the so-called cation hole and favor occupation
fold that bridges the benzamidine and the distal aro-of the aromatic box by basic groups such as amidines
matic rings that is positioned above the peptide back-or other positively charged substituents [31].
bone of residues 214–216 and is not able to form theBased on the assumption that simultaneous inhibition
canonical hydrogen bonds with it.of the two key components of the blood coagulation
cascade would be therapeutically advantageous and
based on the presence of a fair structural similarity of Factor Xa – BIBT0871 Complex
the active sites of the two proteinases, we started a The exocyclic torsion angles within the diatomic bridge
medicinal chemistry program concerned with the search connecting the benzamidine and benzimidazole ring
for potent, orally bioavailable, dual specific inhibitors of systems (at the aniline nitrogen 2178, at the carbon atom
thrombin and factor Xa. 1018) suggest that the inhibitor is bound in a low energy
In our design of these inhibitors, we used 4-(1-methyl- conformation (Figure 3). As a result, the N-H vector is
benzimidazole-2-yl)-methylamino-benzamidine as the pointing toward the side chain of Ser-195 forming a
basic scaffold (Figure 1). This molecular fragment turns hydrogen bond interaction with the serine hydroxyl
out to be ideally suited to meet the steric requirements group. The 1-methyl-benzimidazole scaffold lies flat on
for fitting equally well into the S1 and S2 pockets of the protein surface above Gly-216 and places the methyl
thrombin and factor Xa. The exploration of distal substit- substituent into the S2-subsite. The S4-subsite of factor
uents on the inhibitor scaffold fitting into the S4 subsites Xa is occupied by the pyridinyl moiety of BIBT0871,
of both enzymes generated molecules that simultane- which is positioned such that it forms an aromatic stack-
ously inhibit very efficiently both thrombin and factor ing interaction with Phe-174 (ring distance 3.6 A˚) and
Xa. The most potent example of this series, BIBM1015, an edge-on interaction with Trp-215 (distance 3.8 A˚).
exhibits inhibition constants in the low nanomolar range. The structure of the enzyme active site is changed
Here, we describe, for the first time in a comparative slightly concomittant to inhibitor ligation, suggesting an
fashion, the binding mode of two inhibitors of this familiy induced fit type binding mechanism. The factor Xa S1-
in thrombin, factor Xa and trypsin. As it turns out, the subsite in the BIBT0871 complex is narrower compared
molecules bind in two distinct conformations to throm- to that of the self-complexed form of factor Xa, which,
bin and factor Xa/trypsin, respectively. The crystal struc- in the particular tetragonal crystal form described [27],
tures explain the structural cause for the dual inhibition is filled with the C-terminal arginine residue of the EGF2
properties and experimentally verify that trypsin may domain of a neighboring, symmetry equivalent mole-
serve as a potent active site surrogate for factor Xa as cule. However, a comparison with the other inhibitor
previously suggested [32]. bound structures of factor Xa [31, 34] reveals that the
narrow S1-subsite circumference is probably the re-
laxed conformation and that the rigid body motion ofResults
residues 190–194 around the oxyanion hole may be in-
duced by the particular interaction with the EGF2 C-ter-While for thrombin and trypsin an abundance of cocrys-
tal structures have been reported [33], to date only few minal peptide chain in the self-complexed form [27].
Coagulation Inhibitors Complex Structures
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Table 1. Data Collection and Refinement Statistics
Factor Xa Thrombin Trypsin
BIBT0871 BIBR1109 BIBT0871 BIBR1109 BIBT0871 BIBR1109
Data Collection
Temperature (K) 100 293 100 100 100 100
Space group P212121 P212121 C2 C2 P212121 P212121
Cell, a, b, c (A˚) 56.2, 72.7, 76.7 57.4, 73.2, 79.7 69.3, 70.9, 72.8 69.6, 70.9, 72.9 63.2, 69.3, 63.8 63.1, 69.4, 63.8
b (8) 100.3 100.4
Max resolution 1.9 3.0 2.0 1.9 1.9 1.9
No. of observations 102,600 54,275 53,146 43,458 60,354 75,541
Unique reflections 25,371 6,623 22,489 25,611 21,559 22,243
Completeness (%) 99.3 94.4 94.8 92.2 94.9 97.8
Rm (%) 5.5 12.2 5.5 5.7 4.6 6.9
Refinement
Resolution range (A˚) 20.–1.9 20.–3.0 20.–2.0 20.–1.9 8.–1.9 8.–1.9
No. of reflections 25,049 6,609 22,064 25,246 21,314 21,927
R, RF (%) 23.7/27.2 21.8/27.8 21.0/26.4 20.9/28.9 17.6/22.1 17.4/21.6
Protein atoms 2,267 2,267 2,359 2,359 1,629 1,629
Ca, SO4 1, – 1, – –, – –, – 1, 1 1, 1
Inhibitor atoms 38 32 38 32 38 32
Water molecules 213 – 195 313 168 176
Rmsd bonds (A˚) 0.007 0.005 0.008 0.009 0.008 0.008
Rmsd angles (8) 1.27 1.53 1.76 1.80 1.78 1.81
Bav (A˚2) 37.2 22.0 25.6 28.6 21.4 19.8
Rmsd bonded B (A˚2) 1.4 3.9 2.8 2.5 2.2 1.8
PDB entry code 1G2L 1G2M 1G30 1G32 1G34 1G36
To create space for the N-methyl group and the ben- avoid sterically unfavorable contacts. The His-57 side
chain is shifted by 1.1 A˚ toward the protein interior andzene ring of the central benzimidazole scaffold at the
S2-subsite, the side chain of Tyr-99 is moved over by thereby conserves its hydrogen bonding with Ser-195.
The 60-loop is shifted by about 2 A˚ toward the catalytica rotation of 558 around its side chain x2 torsion angle,
which leads to a slight expansion of the S2-subsite. This triad residues His-57 and Ser-195 and closes in on the
hydrophobic N-methyl-benzimidazole fragment of thecreates a small depression into which the methyl group
perfectly fits. inhibitor within the active site cleft of the enzyme. The
occupation of the S4 subsite with the pyridyl substituentThe 99-loop at the back of the S4-subsite is shifted
backward slightly by 1.1 A˚ generating the space neces- forces the 99-loop of thrombin to move back slightly
with respect to the unliganded form of the proteinase.sary for accommodating the pyridine ring.
Thrombin–BIBT0871 Complex Factor Xa/Thrombin–BIBR1109 Complexes
BIBR1109 differs from BIBT0871 in the distal fragment,In contrast to the conformation observed in factor Xa,
BIBT0871 utilizes a different conformation about the which is a second 1-substituted benzimidazole system
(Figure 1.). In complex with thrombin and factor Xa thisdiatomic bridge connecting the benzamidine and the
benzimidazole (Figure 4). Here, the corresponding tor- inhibitor binds in an identical conformation in both cases
with the benzene ring of the benzimidazole occupyingsion angles are 21388 at the aniline nitrogen and 2168
at the carbon atom, relative to the situation in factor Xa a the position of the pyridyl ring and the imidazole ring
the site of the oximether of BIBT0871 (Figure 2).slightly more unfavorable conformation. Consequently,
the inhibitor N-H bond vector points toward bulk solvent
and the methylene group is placed close to His-57 and Trypsin Complexes
Trypsin has been utilized as a readily crystallizable ac-Ser-195 on the protein surface. The plane of the aromatic
N-methyl-benzimidazole scaffold is oriented perpendic- tive site surrogate for factor Xa and other trypsin-like
serine proteinases [32, 36, 37]. We have determined theular to the protein surface at Gly-216 and the methyl
substituent is positioned between residues His-57, Tyr- crystal structures of both synthetic inhibitors as being
bound to trypsin to check the validity of this approach60A, and Trp-60D deep within the S2-subsite. The pyridi-
nyl group is centered in the aryl binding pocket where by direct comparison to the experimentally determined
structure of factor Xa in complex with the same inhib-it forms an edge–on aromatic interaction with Trp-215
and alkyl-p-interactions with Ile-174. itors.
As it turns out, the bound conformations of the inhibi-Compared to apo-thrombin, pronounced structural
rearrangements of the protein are induced by ligand tors are identical in trypsin and factor Xa (Figure 5).
Here, as in factor Xa, the NH . . . Og Ser-195 interactionbinding. Most prominently, due to the conformation
around the aniline nitrogen, the position of the neigh- is formed by adoption of the identical conformation
about the diatomic bridge. Structural adaptations of theboring methylene group forces the side chain of Ser-
195 to adopt a different conformation with the hydroxyl proteinase upon ligand binding are minimal in trypsin.
This may be due to the larger size of its S2-site due togroup moved by rotation about the x1 torsion angle to
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Figure 2. Experimental Evidence for the
Bound Conformation of the Ligands to their
Protein Receptors
Difference electron density maps (contoured
at 2s) of BIBT0871 (left column) and
BIBR1109 (right column) in the active sites of
factor Xa, trypsin and thrombin (from top to
bottom) superimposed on the final structures.
the absence of Tyr-99 (which is Leu-99 in trypsin) and The bound conformations of the inhibitors are identi-
cal in factor Xa and trypsin but distinct from the bindingbecause the aryl binding site is not confined by spacious
residues but rather flat and solvent accessible. mode utilized when the inhibitors bind to thrombin (Fig-
ure 6).
While the active site of trypsin is rather flat in the S2-Discussion
and S4-subsite areas and allows for a relaxed bound
inhibitor conformation, the clefts of thrombin and factorTwo inhibitors with a mixed inhibition profile toward the
Xa are rather deep and impose severe restrictions onblood coagulation proteinases thrombin and factor Xa
the available space to be occupied by the inhibitor.were cocrystallized with the proteinases thrombin, fac-
Thus, to occupy the proximal S2-pocket of thrombintor Xa, and trypsin.
with its N-methyl-benzimidazole group while main-The inhibitor structures allow for efficient occupation
taining the favorable ionic interactions in the specificityof the S1- and S4- subsites of the enzymes, however,
pocket, the inhibitor has to adopt the observed thrombinfunctional groups for the formation of the canonical
bound conformation which places the NH group intohydrogen bonding interactions observed for peptide de-
bulk solvent without the possibility of forming a hydro-rived inhibitors [25, 38] are absent. In contrast to pub-
gen bond with Ser-195 OH. This conformation of thelished factor Xa specific inhibitors [31], the 1-methyl-
proximal inhibitor fragment in turn, however, allows anbenzimidazole moiety provides a methyl group for the
optimal occupation of the distal aryl binding site.occupation of the small S2-subsite of this proteinase,
In factor Xa, the main restriction imposed on the inhibi-which predominantly cleaves peptide sequences with
glycine at P2 [1, 39, 40]. tor is the maintenance of the S1-subsite interaction of
Coagulation Inhibitors Complex Structures
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Figure 3. Structure of Ligand Bound Factor Xa and Comparison with the Unliganded Proteinase
Stereo representation of BIBT0871 (orange carbon atoms) in complex with factor Xa (blue carbon atoms) and superimposed on the active
site structure of apo-factor Xa (gray carbon atoms). Changes of the protein structure mainly involve a shift of residues 190-194 forming the
lower rim of the specificity pocket and side chain reorientations of Tyr-99 and Phe-174. The former may be a results of a distortion of apo-
factor Xa in the self-inhibited crystal structure, the latter probably reflects real inhibitor induced changes to create space in the S2-subsite
region (Tyr-99) and to optimize aromatic interactions in the S4 subsite (Phe-174).
the benzamidine with the Asp-189 carboxylate and fur- ent from the thrombin case, but seems equally well
suited for optimal occupation of this site.ther to put the methyl substituent of the benzimidazole
into the S2-subsite as a P2 surrogate. This is possible Inhibition constants toward thrombin and factor Xa
for the two cocrystallized inhibitors are reported in Tablewhile maintaining the favorable interaction of the aniline
NH with Ser-195 OH. The resulting trajectory for the 2. While the Ki’s are submicromolar for the target en-
zymes, no selectivity against trypsin is observed. Thedistal substituent into the aromatic S4-pocket is differ-
Figure 4. Structure of Ligand Bound Thrombin and Comparison with the Unliganded Proteinase
Stereo representation of BIBT0871 (orange carbon atoms) in complex with thrombin (blue carbon atoms) and superimposed on the active
site structure of apo-thrombin (PDB-code: 1HAH; gray carbon atoms). Ligand-induced changes involve rearrangements of the catalytic residues
Ser-195 and His-57, a shift of residue Trp-60D above the inhibitors methyl-benzimidazole moiety and a reorientation of the 99-loop in the back
of the S4-subsite.
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Figure 5. Comparison of the Inhibitor Conformations as Bound to Factor Xa and Trypsin
Stereo representation of BIBR1109 (green carbon atoms) in complex with trypsin (gray carbon atoms) and superimposed on the active site
structure of BIBR1109 (magenta carbon atoms) in complex with factor Xa (orange carbon atoms). The inhibitor conformations are identical
between the two structures.
observed selectivity of the inhibitors toward the fibrino- methylamino-benzamidine moiety, the binding mode of
this compound to factor Xa and thrombin is identicallytic enzymes (plasmin, urokinase, and tPA) of 2–3 or-
ders of magnitude may be sufficient for excluding any to the described binding modes of BIBR1109 and
BIBT0871 as shown by its cocrystal structures witheffect compromising their anticoagulant activity in vivo.
The lack of selectivity toward trypsin, present in the thrombin and trypsin (data not shown). BIBM1015 exhib-
its Ki values of 15 nM for factor Xa and 20 nM for throm-gastrointestinal duct, is anticipated to be of no concern
for the following reason. The strong hydrophilic charac- bin and represents one of the most potent dual inhibitors
reported to date. It serves as a starting point for anter of the compounds results in low oral bioavailabilities
of the presented compounds (data not shown). How- optimization program for combined factor Xa/thrombin
inhibitors in our group.ever, modification of the active principle to a prodrug
form by chemical masking of the charged groups pro- The comparative analysis of 3D structures of inhibitors
bound to thrombin, factor Xa and trypsin further deep-duces biologically inactive molecules that are resorbed
after oral administration. The prodrugs will not interfere ens the understanding of the scope and limitations of
the active site surrogate approach for trypsin-like pro-with the trypsin activity in the gastrointestinal duct, but
are converted to the active compounds by enzymes teinases using trypsin cocrystal structures. They show
that for the presented and similar types of syntheticpresent in the gastrointestinal wall, blood, or liver.
The factor Xa inhibition was determined to be about inhibitors, trypsin may indeed be used as an active site
model for factor Xa, but it may not yield relevant results3- to 15-fold more efficient relative to thrombin inhibi-
tion. In the light of the described structures, the potency for the thrombin bound conformations.
The present work shows that inhibitors exhibiting aagainst factor Xa is in part based on a favorable solvent
shielded NH–Og Ser-195 interaction. This is in line with mixed activity profile toward thrombin and factor Xa
utilize different binding conformations albeit similar mo-the observed structure activity relationships for other
classes of substituted benzamidines with hydrogen lecular interactions with the proteinases. By elucidating
these distinct binding modes of identical inhibitors asbond donors in the para-position [41]. The potency
against thrombin, in contrast, is based mainly on a large being bound to the two enzymes, most useful informa-
tion is obtained for the design of a new generation ofarea of buried hydrophobic surface with the 1-methyl-
benzimidazole fitting snugly into the S2-pocket of the potent antithrombotic drugs directed against the two
key proteinases of the blood coagulation cascade.enzyme.
In a search for more potent inhibitors of this family,
we were able to identify a suitable substitution of the Biological Implications
aromatic residues binding to the S4-pockets of thrombin
and factor Xa by a sterically less demanding pyrrolidine The search for potent orally bioavailable anticoagulants
as effective drugs in thromboembolic disorders such asamide as realized in BIBM1015 (Figure 1 and Table 2).
Due to the conserved 4-(1-methyl-benzimidazole-2-yl)- deep vein thrombosis and in the prevention of venous
Coagulation Inhibitors Complex Structures
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Figure 6. Comparison of the Inhibitor Conformations as Bound to Factor Xa and Thrombin
Stereo representation of BIBT0871 (green carbon atoms) in complex with thrombin (blue carbon atoms) and superimposed on the active site
structure of BIBT0871 (magenta carbon atoms) in complex with factor Xa (orange carbon atoms). This superposition reveals the distinct
conformations of the inhibitor structures proximal to Ser-195, which places the benzimidazole fragments in two different positions. Nevertheless,
the distal aromatic substituents are in very similar positions in the S4-subsite of the two enzymes.
and arterial thrombosis is currently a major focus of stroke and infections, are based on the administration of
combinations of two or more compounds. Third, heparinpharmaceutical research. In the past, selective inhibitors
of thrombin or other actors in the blood coagulation and low molecular weight heparin, the most important
anticoagulatory agents in today’s clinical use, representcascade such as factor Xa, factor IXa, or factor VIIa
have been sought and, in the case of thrombin and factor examples of coagulation inhibitors that combine in them-
selves multiple mechanisms of action, albeit through anXa, are being studied in the early clinical development
phases. indirect action on thrombin and factor Xa via the serpin
antithrombin III. Fourth, a potent direct dual specificA combination of the effects of thrombin and factor
Xa inhibitors as a novel approach to the therapy of inhibitor may be therapeutically effective at lower plasma
concentrations compared to selective inhibitors. Finally,thromboembolic disorders appears to be an attractive
goal in antithrombotic research for various reasons. a compound that combines two modes of action in a
single chemical entity carries additional advantagesFirst, blood sucking animals have developed strategies
to prevent blood clotting by simultaneous inhibition of over the combination of separate compounds by facili-
tating clinical testing and registratory matters.two or more procoagulatory factors suggesting that
mimicking such an evolutionarily developed approach The search for anticoagulant drugs has been effi-
ciently guided by the knowledge derived from knownby the invention of synthetic agents with a similar inhibi-
tion profile may be similarly successful in therapeutic 3D structures of the targeted serine proteinases. Based
on the similarity of the active site structures of thrombinapplications. Second, several effective therapeutic ap-
proaches, such as the treatments of HIV (protease and and factor Xa and based on the above reasoning, we
have set out to explore whether it is possible to designreverse transcriptase inhibitors) [42], hypertension [43],
Table 2. Ki, Selectivity Data
Ki (nM) BIBT0871 BIBR1109 BIBM1015
Factor Xa 57 (3) 40 (1) 15 (1)
Thrombin 140 (10) 780 (50) 20 (2)
Trypsin 110 (5) 67 (3) 102 (10)
Two-chain urokinase 44,000 16,000 6,500
Plasmin 6,800 9,200 13,000
Factor XIa 9,000 4,100 8,200
Factor VIIa/tissue factor .40,000 .40,000 .40,000
Tissue type plasminogen activator .50,000 .50,000 .30,000
Data are the Ki mean values and standard deviations (in parentheses) calculated from 12 independent determinations for the target enzymes
factor Xa, thrombin and trypsin (6 for the selectivity data against the bottom 5 proteases).
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Table 1. The coordinates and structure factors have been depositedinhibitors that are similarly effective against both en-
with the Protein Data Bank (PDB entry codes are listed in Table 1).zymes.
Here, we describe the crystal structures of two inhibi-
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